Skip to content

Potato Fiber and Gastrointestinal Function: Phase 3

Potato Fiber and Gastrointestinal Function: Phase 3 (Grant #94521)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01964599
Enrollment
90
Registered
2013-10-17
Start date
2014-01-31
Completion date
2014-04-30
Last updated
2017-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Symptoms, Gastrointestinal Transit Time, Stool Frequency

Keywords

Fiber, Gastrointestinal

Brief summary

The primary physiological impacts of fiber intake include the gastrointestinal effects of stool bulking, increased stool frequency and decreased gastrointestinal transit time (GTT). Fermentation of resistant starches by microbiota increases bacterial numbers, which increases fecal bulk and may impact frequency and transit time. The purpose of this study is to determine the effects of resistant potato starches (potato fiber) on stool frequency, transit time and microbiota in healthy individuals.

Detailed description

Potato fiber (PF-RS, PF-RO1 and PF-RO2), supplemented in the diet of healthy individuals (n=60; 20 per group) and providing 30 g per day of fiber, will result in a significant changes in gastrointestinal function and microbiota profile. Objectives: 1. To determine the effect of potato fibers on stool frequency, gastrointestinal transit time and gastrointestinal symptoms. 2. To determine the effect of potato fibers on microbial diversity in healthy individuals.

Interventions

DIETARY_SUPPLEMENTPF-RS

n=20 will consume PF-RS containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.

DIETARY_SUPPLEMENTPF-RO1

n=20 will consume PF-RO1 containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.

DIETARY_SUPPLEMENTPF-RO2

n=20 will consume PF-RO2 containing 30 g potato fiber for 14 days and then will consume a control containing no fiber for 14 days.

DIETARY_SUPPLEMENTControl

Sponsors

University of Florida
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* must be between the ages of 18 and 65. * must be willing to complete daily questionnaires. * must be willing to provide a social security number to receive study payment. Note: the subject can still participate if unwilling to provide SS#, but no financial reimbursement can be provided. * must have internet access for the duration of the study * must have usual fiber intake of \<20 g/d based on Food Frequency Questionnaire such as the Block Fruit/Vegetable/Fiber Screener * must be willing to consume kool-aid everyday for 2 periods of 14 days * must be willing to provide stool samples

Exclusion criteria

* must not have a physician-diagnosed gastrointestinal disease or condition (such as ulcerative colitis, Crohn's disease, gastroparesis, cancer, peptic ulcer disease, Celiac disease, short bowel disease, ileostomy, colostomy other than GERD, constipation, diverticular disease) * must not have a food allergy * must not take dietary supplements (prebiotic and fiber supplements)

Design outcomes

Primary

MeasureTime frameDescription
Stool Frequency6 weeksChange in stool frequency determined by the daily questionnaire

Secondary

MeasureTime frameDescription
Gastrointestinal transit time6 weeksChange in gastrointestinal transit time determined by the Bristol Stool Scale
Gastrointestinal symptoms6 weeksChange in gastrointestinal symptoms determined by the daily questionnaire
Microbial diversity6 weeksBaseline, treatment, control and washout stools (for a total of 6 samples) for each subject will be sampled for DNA isolation for microbiota studies. Microbial diversity measured by DGGE profiling (detects large distortions), qPCR to quantify changes and 16S rRNA sequencing (454) to identify treatment effects on specific bacteria (discovery) will be undertaken.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026